Creative Medical Technology Holdings Inc
CELZ
View Detailed Chart
1.960USD
-0.020-1.01%
Market hours （ET）Quotes delayed by 15 min
47.34Market Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.01%
5 Days
+6.52%
1 Month
+8.29%
6 Months
-40.79%
Year to Date
0.00%
1 Year
-13.66%
View Detailed Chart
TradingKey Stock Score of Creative Medical Technology Holdings Inc
Currency: USD Updated: 2026-03-27Key Insights
Creative Medical Technology Holdings Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 129 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 20.00.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Creative Medical Technology Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Creative Medical Technology Holdings Inc Highlights
StrengthsRisks
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
Growing
The company is in a growing phase, with the latest annual income totaling USD 6.00K.
Fairly Valued
The company’s latest PE is -0.78, at a medium 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 25.87K shares of this stock.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
20.000
Target Price
+910.10%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Creative Medical Technology Holdings Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Creative Medical Technology Holdings Inc Info
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.
Ticker SymbolCELZ
CompanyCreative Medical Technology Holdings Inc
CEOWarbington (Timothy)
Websitehttps://creativemedicaltechnology.com/
Related Instruments
-0.85%
+1.25%
+1.38%
+2.95%
+0.20%
+1.61%
+0.28%
+0.42%
+0.64%
+1.27%
+1.81%
0.00%
+0.78%
+1.94%
-2.95%
0.00%
+0.37%
+2.08%
+2.01%
-1.64%Popular Symbols
246.525
-2.275 (-0.91%)
167.385
-0.135 (-0.08%)
67689.180
+1105.130 (+1.66%)
258.680
-16.660 (-6.05%)
2068.710
+68.710 (+3.44%)
362.800
+0.970 (+0.27%)
4538.270
+45.750 (+1.02%)
101.252
+0.643 (+0.64%)
1.146
-0.005 (-0.40%)
159.535
-0.717 (-0.45%)
